Table 1.
Baseline information of patients with LVADs using SGLT2-i.
| Study | N | Age, Years | Male | Duration of Support (Duration of LVAD) | INTERMACS Level | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||||
| Cagliostro et al., 2022 [7] | 34 | 56.1 ± 10.6 | 27 (79.4%) | - | 5 (15.6%) | 5 (15.6%) | 19 (59.4%) | 3 (9.4%) | 0 (0%) |
| Chavali et al., 2023 [5] | 16 | 52.25 (46.71–57.93) | 15 (93.75%) | 212 (133–324) days | 6 (37.5%) | 3 (18.75%) | 3 (18.75%) | 4 (25%) | 0 (0%) |
| Moady et al., 2023 [6] | 20 | 64.7 ± 12.2 | 15 (75%) | - | 2 (10%) | 5 (25%) | 8 (40%) | 5 (25%) | 0 (0%) |
| Fardman et al., 2024 [21] | 29 | 62 ± 6.7 | 25 (86.2%) | - | 2 (6.9%) | 9 (31%) | 12 (41.4%) | 6 (20.7%) | 0 (0%) |
| Conference abstracts | |||||||||
| Hambright et al., 2022 [16] | 21 | - | - | - | - | - | - | - | - |
| Acosta et al., 2022 [14] | 15 | - | - | - | - | - | - | - | |
| Yaranov et al., 2022 [17] | 9 | 54 | 36 (67%) | - | - | - | - | - | - |
| Chavali et al., 2022 [15] | 12 | - | - | - | - | - | - | - | - |
| Byczkowska et al., 2023 [18] | 51 | 60 ± 3.5 | 51 (100%) | - | - | - | - | - | - |
| Lanham et al., 2023 [19] | 1 | 42 | 1 (100%) | - | - | - | - | - | - |
| Al Ali et al., 2024 [20] | 20 | 59 ± 11 | 17 (85%) | - | - | - | - | - | - |
Data are presented as numbers (percentages); Mean ± SD; Median (IQR). Abbreviations: INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; IQR: Interquartile Range; LVAD: Left Ventricular Assist Device; SD: Standard Deviation; SGLT2-i: Sodium-Glucose Co-Transporter-2 Inhibitors.